Growth and metabolic disturbances in a patient with total parenteral nutrition: a case of hypercalciuric hypercalcemia.
Hypercalciuria is a common side effect during total parenteral nutrition (TPN). We report a patient with long-term TPN, who demonstrated hypercalciuria, hypercalcemia and growth retardation. The patient is a six-year-old Japanese girl with Hirschsprung disease (jejunal agangliosis). Jejunostomy was performed at one-month old and since then her nutrition has depended mostly on TPN. When she was 3 years old, continuous TPN was switched to cyclic TPN (on TPN for 11 hrs and off TPN for 13 hrs). The urinary calcium level has been elevated (Ca/Cre ratio, 1.0) since 3 months of age, whereas serum calcium levels stayed within normal range for a while. The serum calcium levels started to elevate to 12 to approximately 13 mg/dl when she was 3 years and 8 months old. She showed growth retardation (height SD score was -4.2SD when she was 5 years and 8 months old) and deteriorated renal tubular function with renal glycosuria, elevated beta 2-microglobulin (beta2-MG) and N-acetyl-beta-D-glucosaminidase. She was referred to our division for the investigation and treatment of growth disturbance and Ca metabolism. Her bone age was delayed (BA/CA 0.62) and serum IGF-I level was decreased but her GH response to provocation test was normal. Bilateral nephrocalcinosis was revealed by renal echogram and CT scan. By reducing calcium content in TPN solution, the serum and urinary calcium levels could be maintained within normal range and her renal function and growth velocity was improved.
Ikema
S
S
Division of Endocrinology and Metabolism, National Children's Hospital, Tokyo, Japan.
Horikawa
R
R
Nakano
M
M
Yokouchi
K
K
Yamazaki
H
H
Tanaka
T
T
Tanae
A
A
D002118:Calcium / Q000008:administration & dosage / Q000652:urine*; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000209:etiology*; D006627:Hirschsprung Disease / Q000628:therapy; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology* / Q000652:urine*; D008659:Metabolic Diseases / Q000209:etiology*; D009397:Nephrocalcinosis / Q000097:blood / Q000209:etiology / Q000628:therapy / Q000652:urine; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*; D012996:Solutions / Q000008:administration & dosage / Q000737:chemistry; D016896:Treatment Outcome
D012996:Solutions; D002118:Calcium